Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Chlamydia trachomatis | dihydrofolate reductase | 0.452 | 1 | 0.5 |
Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase | 0.2568 | 0.4987 | 0.5 |
Trypanosoma brucei | dihydrofolate reductase-thymidylate synthase | 0.2568 | 0.4987 | 0.5 |
Echinococcus granulosus | thymidylate synthase | 0.0671 | 0.0115 | 0.0115 |
Schistosoma mansoni | dihydrofolate reductase | 0.452 | 1 | 1 |
Echinococcus multilocularis | thymidylate synthase | 0.0671 | 0.0115 | 0.0115 |
Echinococcus granulosus | dihydrofolate reductase | 0.452 | 1 | 1 |
Echinococcus multilocularis | dihydrofolate reductase | 0.452 | 1 | 1 |
Onchocerca volvulus | 0.0671 | 0.0115 | 0.5 | |
Loa Loa (eye worm) | dihydrofolate reductase | 0.452 | 1 | 1 |
Toxoplasma gondii | bifunctional dihydrofolate reductase-thymidylate synthase | 0.2568 | 0.4987 | 0.5 |
Mycobacterium leprae | DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) | 0.452 | 1 | 1 |
Plasmodium vivax | bifunctional dihydrofolate reductase-thymidylate synthase, putative | 0.2568 | 0.4987 | 0.5 |
Leishmania major | dihydrofolate reductase-thymidylate synthase | 0.2568 | 0.4987 | 0.5 |
Mycobacterium tuberculosis | Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) | 0.452 | 1 | 1 |
Brugia malayi | Dihydrofolate reductase | 0.452 | 1 | 1 |
Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | 0.2568 | 0.4987 | 0.5 |
Mycobacterium ulcerans | dihydrofolate reductase DfrA | 0.452 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | = 170 nM | Tested in vitro for GH-releasing potency against rat pituitary cells. | ChEMBL. | 9733495 |
ED50 (functional) | > 1000 nM | Compound was tested in vivo for GH-releasing potency against anesthetized female rats | ChEMBL. | 9733495 |
Emax (functional) | = 85 % | Tested in vitro for GH-releasing potency against rat pituitary cells. | ChEMBL. | 9733495 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.